000 males with nonmetastatic prostate cancer.

During follow-up, 232 instances with a first-ever AKI admission were identified. All whole situations were matched with at least l control. The researchers discovered that weighed against never use, current usage of ADT was significantly associated with a 2.5 times increased probability of AKI. ‘This association was mainly driven by a combined androgen blockade consisting of gonadotropin-releasing hormone agonists with oral antiandrogens, estrogens, various other combination therapies, and gonadotropin-releasing hormone agonists.’ ‘To our knowledge, this is actually the first population-based study to investigate the association between the use of ADT and the risk of AKI in males with prostate tumor... ARIAD provides update on corporate developments, reviews Q1 2014 financial results ARIAD Pharmaceuticals, Inc. The Company also provided an update on corporate developments. As we reintroduce Iclusig in to the U.S. Market and continue with the European launch this full year, our crucial priorities are to rebuild confidence in Iclusig also to improve the benefit/risk profile of the drug, said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. Early start data in the U.S. Represent approximately 10 weeks of advertising with a revised product label and show solid market support for Iclusig from community and academic doctors and across a broad spectrum of patients with Philadelphia-positive leukemias.